Gilead Sciences shows positive results for remdesivir as COVID-19 drug
Category: #health  By Mateen Dalal  Date: 2020-05-01
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Gilead Sciences shows positive results for remdesivir as COVID-19 drug

Gilead Sciences, the maker of remdesivir, has recently revealed positive results from trials for the drug. The trials were conducted to evaluate the potential of the medication as a treatment for the novel coronavirus.

The trials examined the response of patients to either 5-day or 10-day treatments of remdesivir. According to Gilead, the patients undergoing the 5-day treatment showed similar improvement as those treated for twice the timeframe.

Merdad Parsey, Gilead Sciences’ chief medical officer has reportedly stated that the trial shows the potential of certain patients to be treated under the 5-day remdesivir regimen, which could considerably increase the number of patients that could be treated with the present remdesivir supply. This could prove extremely beneficial in the current pandemic setting, enabling healthcare facilities and hospitals to provide efficient treatment to patients in urgent need.

The drug is also being tested locally. For instance, St. Joseph Hospital revealed its plans to conduct some remdesivir trials earlier in the month, which marks a significant feat for the small rural facility. The hospital is conducting two clinical trials, one for moderate symptoms and one to treat more severe symptoms.

Chief executive of St. Joseph Health, Dr. Roberta Luskin-Hawk, stated that one of the patients to receive the treatment was a local patient hospitalized at the St. Joseph Hospital, exhibiting severe COVID-19 symptoms, including dropping oxygen, making them an ideal trial candidate. Dr. Luskin-Hawk also expressed her belief that the drug shows promise as a potential COVID-19 treatment. She also recounted her anticipation to gain access to the drug, in order to leverage its ability to reduce viral loads in patients, especially those suffering from the coronavirus.

The hospital has not offered further information regarding the local trials.

There are no medications currently approved for the treatment of COVID-19, a respiratory disorder that has claimed the lives of over 227,000 people across the globe.

Source Credit: https://www.times-standard.com/2020/04/29/covid-19-drug-shows-promise-in-two-clinical-trials/

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

China unveils plans to reinforce stringent safety standards for EVs

China unveils plans to reinforce stringent safety standards for EVs

By Mateen Dalal

This news comes amid rising incidences of battery fires and breaks failures. China will require automakers to have a 24-hour emergency response system to address major accidents. China is planning to reinforce strict safety standards for electri...

Facebook testing new option for cross-posting content to Instagram

Facebook testing new option for cross-posting content to Instagram

By Mateen Dalal

Facebook, Inc is reportedly testing an option that will allow users to cross-post their photos, videos, and other posts on their Instagram. It already has the feature to let people cross-post their Instagram content to Facebook. This upcoming featur...

General Motors to recoup USD 1.9 Bn from LG spent on Bolt EV recall

General Motors to recoup USD 1.9 Bn from LG spent on Bolt EV recall

By Mateen Dalal

GM will recover almost all the costs from the recall of its Bolt EV models. Despite the EV battery manufacturing mishap from LG, the two companies will continue to work together. General Motors (GM) has agreed to recover around USD 1.9 billion f...